It has been shown to be overexpressed in diverse cancers and contributes to cancer development and progress as an oncogene, thus, inhibition of KDM1A pharmacologically can suppress the proliferation and migration of diverse cancer cells (Zheng et al., 2015; Zheng et al., 2016c; Dai et al., 2020; Jia et al., 2020). Here, KDM1A is linked to cancer.